<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00661739</url>
  </required_header>
  <id_info>
    <org_study_id>GBG 38</org_study_id>
    <nct_id>NCT00661739</nct_id>
  </id_info>
  <brief_title>A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer</brief_title>
  <acronym>RiTa</acronym>
  <official_title>A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>German Breast Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>German Breast Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to establish a feasible combination of bendamustine and paclitaxel in&#xD;
      a weekly schedule. The two agents have different toxicity profiles and are well tolerated&#xD;
      when given in a weekly fashion. The combination might be of special interest for elderly&#xD;
      patients with hormone insensitive breast cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The phase I part of the trial should evaluate the maximal tolerated dose (MTD) for the combination of bendamustine with paclitaxel.</measure>
    <time_frame>end of cycle 2 of the 6th patient of the assumed highest dose level</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the objective response rate (phase II part)</measure>
    <time_frame>EOT last patient (phase II part)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Singular Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendamustine treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.</description>
    <arm_group_label>Singular Arm</arm_group_label>
    <other_name>Ribomustine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent must be obtained and documented according to the local&#xD;
             regulatory requirements prior to beginning specific protocol procedures;&#xD;
&#xD;
          -  Pathological confirmed primary carcinoma of the breast.&#xD;
&#xD;
          -  Locally advanced or metastatic disease&#xD;
&#xD;
          -  Up to one previous palliative chemotherapy that did not contain docetaxel or&#xD;
             paclitaxel. Previous adjuvant treatment with taxanes is allowed when the last&#xD;
             application of the taxane was given at least 1 year before entering the trial.&#xD;
&#xD;
          -  Patients must have either measurable or non-measurable lesions according to the WHO&#xD;
             criteria&#xD;
&#xD;
          -  At least 4 weeks since radiotherapy, with full recovery. The measurable disease must&#xD;
             be completely outside the radiated field or there must be pathological proof of&#xD;
             progressive disease.&#xD;
&#xD;
          -  Complete radiological and clinical tumor assessment within 4 weeks prior to&#xD;
             registration performed as clinically indicated&#xD;
&#xD;
          -  Karnofsky-Index ≥ 60 %&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,500 cells/µl, platelets ≥ 100,000/µl, and hemoglobin ≥ 9&#xD;
             g/dl&#xD;
&#xD;
          -  Bilirubin within normal limits; evaluation of transaminases and alkaline phosphatase ≤&#xD;
             5x upper normal limit&#xD;
&#xD;
          -  Serum creatinine ≤ 2.0 mg/dl&#xD;
&#xD;
          -  Normal left ventricular ejection fraction (LVEF) by echocardiogramme&#xD;
&#xD;
          -  Patients of childbearing potential, pregnancy test must be negative&#xD;
&#xD;
          -  If fertile effective contraception must be used throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or suspected hypersensitivity reaction to the investigational compounds or&#xD;
             incorporated substances;&#xD;
&#xD;
          -  Concurrent immunotherapy or hormonal treatment for cancer (Bisphosphonates may be&#xD;
             continued)&#xD;
&#xD;
          -  Symptomatic parenchymal brain metastases not responding to treatment&#xD;
&#xD;
          -  Life expectancy less than 3 months&#xD;
&#xD;
          -  Other serious illness or medical condition that may interfere with the understanding&#xD;
             and giving of informed consent and the conduct of the study&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or any other anti-cancer therapy&#xD;
             within the last 28 days;&#xD;
&#xD;
          -  History of congestive heart failure or other significant uncontrolled cardiac disease&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2010</verification_date>
  <study_first_submitted>April 15, 2008</study_first_submitted>
  <study_first_submitted_qc>April 17, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2008</study_first_posted>
  <last_update_submitted>August 31, 2011</last_update_submitted>
  <last_update_submitted_qc>August 31, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>palliative</keyword>
  <keyword>Breast cancer</keyword>
  <keyword>metastatic</keyword>
  <keyword>Bendamustine</keyword>
  <keyword>phase I</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

